APO Research
Talk to an analyst

APO RESEARCH · REPORT

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025181 pages

Choose your research edition.

Industry ResearchCommunity Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug include Merck & Co Inc, Valevia UK Ltd, Syntiron LLC, Galapagos NV and Allergan Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Segment by Company

Merck & Co Inc

Valevia UK Ltd

Syntiron LLC

Galapagos NV

Allergan Plc

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Segment by Type

Acorafloxacin Hydrochloride

Solithromycin

VAL-301

GLPG-1492

Others

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Segment by Application

Hospital

Clinic

Others

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Trends Table 2. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Drivers Table 3. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Opportunities and Challenges Table 4. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Restraints Table 5. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Manufacturers Table 9. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturers, Product Type & Application Table 13. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Acorafloxacin Hydrochloride Table 17. Major Manufacturers of Solithromycin Table 18. Major Manufacturers of VAL-301 Table 19. Major Manufacturers of GLPG-1492 Table 20. Major Manufacturers of Others Table 21. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2021-2026) Table 25. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2027-2032) Table 26. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Type (2021-2026) Table 30. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Others Table 34. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2021-2026) Table 38. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2027-2032) Table 39. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Application (2021-2026) Table 43. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Application (2027-2032) Table 44. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Region (2021-2026) Table 47. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region (2021-2026) Table 65. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region (2027-2032) Table 66. Merck & Co Inc Company Information Table 67. Merck & Co Inc Business Overview Table 68. Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio Table 70. Merck & Co Inc Recent Development Table 71. Valevia UK Ltd Company Information Table 72. Valevia UK Ltd Business Overview Table 73. Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio Table 75. Valevia UK Ltd Recent Development Table 76. Syntiron LLC Company Information Table 77. Syntiron LLC Business Overview Table 78. Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio Table 80. Syntiron LLC Recent Development Table 81. Galapagos NV Company Information Table 82. Galapagos NV Business Overview Table 83. Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio Table 85. Galapagos NV Recent Development Table 86. Allergan Plc Company Information Table 87. Allergan Plc Business Overview Table 88. Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio Table 90. Allergan Plc Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Distributors List Table 94. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Image Figure 2. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (2021-2032) & (K Units) Figure 5. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Acorafloxacin Hydrochloride Image Figure 9. Solithromycin Image Figure 10. VAL-301 Image Figure 11. GLPG-1492 Image Figure 12. Others Image Figure 13. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2021-2032) Figure 16. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2021-2032) Figure 25. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2021-2032) Figure 42. China Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Acorafloxacin Hydrochloride
  • Solithromycin
  • VAL-301
  • GLPG-1492
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Merck & Co Inc
  • Valevia UK Ltd
  • Syntiron LLC
  • Galapagos NV
  • Allergan Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Dynamics
  1. 2.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Trends
  2. 2.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Drivers
  3. 2.3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Opportunities and Challenges
  4. 2.4 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Restraints
3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market by Manufacturers
  1. 3.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturers, Product Type & Application
  7. 3.7 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Tier 1, Tier 2, and Tier 3
4 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market by Type
  1. 4.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Type Introduction
  2. 4.1.1 Acorafloxacin Hydrochloride
  3. 4.1.2 Solithromycin
  4. 4.1.3 VAL-301
  5. 4.1.4 GLPG-1492
  6. 4.1.5 Others
  7. 4.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type
  8. 4.2.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type
  12. 4.3.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Type (2021-2032)
5 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market by Application
  1. 5.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application
  6. 5.2.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application
  10. 5.3.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Application (2021-2032)
6 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region
  1. 6.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region
  1. 7.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region
  2. 7.1.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2021-2032)
  8. 7.2.2 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2021-2032)
  11. 7.3.2 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co Inc
  2. 8.1.1 Merck & Co Inc Company Information
  3. 8.1.2 Merck & Co Inc Business Overview
  4. 8.1.3 Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio
  6. 8.1.5 Merck & Co Inc Recent Developments
  7. 8.2 Valevia UK Ltd
  8. 8.2.1 Valevia UK Ltd Company Information
  9. 8.2.2 Valevia UK Ltd Business Overview
  10. 8.2.3 Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio
  12. 8.2.5 Valevia UK Ltd Recent Developments
  13. 8.3 Syntiron LLC
  14. 8.3.1 Syntiron LLC Company Information
  15. 8.3.2 Syntiron LLC Business Overview
  16. 8.3.3 Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio
  18. 8.3.5 Syntiron LLC Recent Developments
  19. 8.4 Galapagos NV
  20. 8.4.1 Galapagos NV Company Information
  21. 8.4.2 Galapagos NV Business Overview
  22. 8.4.3 Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio
  24. 8.4.5 Galapagos NV Recent Developments
  25. 8.5 Allergan Plc
  26. 8.5.1 Allergan Plc Company Information
  27. 8.5.2 Allergan Plc Business Overview
  28. 8.5.3 Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Portfolio
  30. 8.5.5 Allergan Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Value Chain Analysis
  2. 9.1.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Mode & Process
  6. 9.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Distributors
  9. 9.2.3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst